Clinical Trials Browser

Phase 2 × tislelizumab × Genitourinary × Clear all

NCT07296705 2025-12-22

HARBOR

Phase 2 Recruiting

Muscle Invasive Bladder Cancer (MIBC)

NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT07233252 2025-11-18

Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

Phase 2 Recruiting

Renal Pelvic Carcinoma

NCT04802876 2025-03-21

ACROPOLI

Phase 2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04004221 2024-10-26

Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer

Phase 2 Completed

113 enrolled 15 charts

Locally Advanced or Metastatic Urothelial Bladder Cancer

NCT06630871 2024-10-10

A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT05531123 2024-07-12

Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT06387056 2024-04-26

SEGNO

Phase 2 Recruiting

Locally Advanced Prostate Cancer

NCT06211790 2024-01-18

Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma

Phase 2 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05957757 2023-08-31

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT05775874 2023-03-20

A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC

Phase 2 Unknown

Carcinoma, Transitional Cell

NCT05445648 2022-12-28

CBPTMI

Phase 2 Unknown

Urinary Bladder Neoplasms

NCT04730219 2022-11-30

Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma

Phase 2 Unknown

Carcinoma, Transitional Cell

NCT05401279 2022-08-18

Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer

Phase 2 Unknown

Urothelial Carcinoma Bladder